Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"

Recruiting now · Phase 2

Conditions studied: T Acute Lymphoblastic Leukemia

In brief

T-ALL (T-acute lymphoblastic leukemia) is an aggressive blood cancer, wherein patients who are MRD positive after two courses of induction chemotherapy have poor outcomes. This goal of this study is to determine if Daratumumab can make such T-ALL patients MRD negative. The main questions this study aims to answer are - 1. Whether MRD Positive T-ALL patients can become MRD negative after two doses of daratumumab? 2. Whether MRD Positive T-ALL patients can become MRD negative after four doses of daratumumab? 3. Whether addition of daratumumab can affect the risk of progression or death at 1-year? 4. Whether daratumumab is safe to use? Newly diagnosed patients of T-ALL who are MRD positive after two courses of induction chemotherapy will be eligible to receive daratumumab. These patients will receive two doses of weekly intravenous daratumumab at standard dose (16mg/kg), and will undergo repeat evaluation of MRD from bone marrow one week after the second dose of daratumumab. Patients who become MRD negative will continue chemotherapy as per institutional policy. Those who remain MRD positive will be eligible to receive two additional doses, and will undergo another bone marrow MRD testing one week after the fourth dose. Irrespective of the results after the fourth dose, patients will be continued on chemotherapy as per institutional policy.

Key facts

Study ID

NCT07021677

Run by

Tata Memorial Centre

People needed

18

Starts

2023-08-28

Expected to finish

2026-08-28

Last updated by the study team

2025-06-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults ≥18 - ≤65 years of age
• Baseline diagnosis of T-ALL, including ETP-ALL
• MRD positive (≥0.01%) disease (by flow-cytometry) assessed on BM after two phases of induction chemotherapy in CR-1
• CD38 positive
• Eastern cooperative oncology group (ECOG) performance status ≤2
• Acceptable liver functions, as specified below:
• Total bilirubin <2 times upper limit of normal (ULN); Aspartate transaminase (AST;SGOT), alanine transaminase (ALT;SGPT) <3 ULN
• Subject ready to sign an informed consent form
• Patients with baseline CSF cytology positive, but who have cleared CSF by either modality (cytology or flow cytometry)

You may not qualify if…

• T-LBL (T-lymphoblastic lymphoma) without BM involvement
• Patients with persistently positive CSF cytology after two phases of induction or baseline testicular involvement
• Patients with symptomatic obstructive airway disease, as per assessing clinician
• Presence of an active systemic infection, as per assessing clinician
• New York Heart Association (NYHA) Class III or IV cardiac disease, or left ventricular ejection fraction <40%
• Human immunodeficiency virus (HIV) positive.
• Pregnant or breastfeeding female
• HBsAg positive or HBV-DNA positivity

Where it is running

• Dr.Sumeet Mirgh — Navi Mumbai, Maharashtra, India (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.